Compare Adobe Systems Inc (ADBE) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Amgen, Inc. — how do they compare? Adobe Systems Inc trades at $261 (market cap $108.50B), while Amgen, Inc. trades at $412.21 (market cap $225.71B). The key difference: Amgen, Inc. is far larger — about 2.1× Adobe Systems Inc's market cap, and Amgen, Inc. pays a 2.42% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | AMGN | |
|---|---|---|
Market Cap | $108.50B | $225.71B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $417.20 |
52-Week Low | $193.41 | $271.18 |
Enterprise Value | $109.94B | $269.02B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum above key support at $270. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability with 89.4% gross margins. Recent earnings beats and accelerating revenue growth contrast with mixed sentiment amid AI competition concerns and CEO transition uncertainty.
ADBE presents a compelling value proposition trading below analyst consensus targets with strong cash flow generation, though faces headwinds from AI disruption fears and sector volatility. The stock's current valuation at 15.62 P/E offers potential upside if execution continues, but requires monitoring of competitive threats and leadership stability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
